![Jonathan R. Savidge](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jonathan R. Savidge
Vorstandsvorsitzender bei Syndesi Therapeutics SA
Aktive Positionen von Jonathan R. Savidge
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Vorstandsvorsitzender | - | - |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Vorsitzender | 26.04.2023 | - |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Jonathan R. Savidge
Ehemalige bekannte Positionen von Jonathan R. Savidge
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | 01.06.2013 | - |
UCL Business Ltd.
![]() UCL Business Ltd. Miscellaneous Commercial ServicesCommercial Services UCL Business Plc operates as a technology transfer company. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01.01.2002 | - |
Ausbildung von Jonathan R. Savidge
University of Oxford | Undergraduate Degree |
The University of Manchester | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 6 |
Israel | 2 |
Belgien | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Executive Officer | 2 |
Undergraduate Degree | 1 |
Sektoral
Commercial Services | 4 |
Consumer Services | 3 |
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BICYCLE THERAPEUTICS PLC | Health Technology |
Private Unternehmen | 4 |
---|---|
UCL Business Ltd.
![]() UCL Business Ltd. Miscellaneous Commercial ServicesCommercial Services UCL Business Plc operates as a technology transfer company. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Commercial Services |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Commercial Services |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Health Technology |
- Börse
- Insiders
- Jonathan R. Savidge
- Erfahrung